

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/955,414	09/18/2001	Nancy L. Parenteau	68603-121	1042
23483	7590 07/13/2004		EXAMINER	
WILMER CUTLER PICKERING HALE AND DORR LLP			PREBILIC, PAUL B	
60 STATE ST BOSTON, MA			ART UNIT PAPER NUMBER	
			3738	
			DATE MAILED: 07/13/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

			しょ				
	Application No.	Applicant(s)					
Advisory Action	09/955,414	PARENTEAU ET AL.					
Advisory Action	Examiner	Art Unit					
	Paul B. Prebilic	3738					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
THE REPLY FILED 10 June 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.							
PERIOD FOR RE	EPLY [check either a) or b)]						
a) The period for reply expiresmonths from the mailing date of the final rejection.							
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).							
Extensions of time may be obtained under 37 CFR 1.136(a). The data have been filed is the date for purposes of determining the period of exter 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortener (b) above, if checked. Any reply received by the Office later than three meanined patent term adjustment. See 37 CFR 1.704(b).	sion and the corresponding amount of the d statutory period for reply originally set in	fee. The appropriate extending the final Office action; or	tension fee under (2) as set forth in				
1. A Notice of Appeal was filed on 10 June 2004. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.							
2. The proposed amendment(s) will not be entered because:							
(a)							
(b) ☐ they raise the issue of new matter (see Note below);							
(c) ☑ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or							
(d) they present additional claims without canceling a corresponding number of finally rejected claims.							
NOTE: See Continuation Sheet.							
3. Applicant's reply has overcome the following rejection	ction(s):						
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	d be allowable if submitted in a s	eparate, timely file	d amendment				
5.☐ The a)☐ affidavit, b)☐ exhibit, or c)☐ request for application in condition for allowance because: _		sidered but does NO	OT place the				
6. The affidavit or exhibit will NOT be considered be raised by the Examiner in the final rejection.	cause it is not directed SOLELY	to issues which we	ere newly				
7. For purposes of Appeal, the proposed amendmen explanation of how the new or amended claims w			and an				
The status of the claim(s) is (or will be) as follows							
Claim(s) allowed:							
Claim(s) objected to: <u>5</u> .							
Claim(s) rejected: <u>1-4,6 and 7</u> .							
Claim(s) withdrawn from consideration:							
8. The drawing correction filed on is a) approved or b) disapproved by the Examiner.							
9. Note the attached Information Disclosure Stateme	ent(s)(PTO-1449) Paper No(s).						
10. Other:			20/1				

Primary Examiner U.S. Patent and Trademark Office PTOL-303 (Rev. 11-03)

Continuation Sheet (PTOL-303) 09/955,414

Application No.

Continuation of 2. NOTE: The proposed amendment to claim 3 presents a new 35 USC 112, second paragraph issue because it states that the "layer" comprises collagen. However, claim 1 states that the layer includes fibroblast cells. Therefore, it is not clear whether the fibroblast cells are part of the layer or not..